We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
27 Oct 2021 - 29 Oct 2021

Heparin-Binding Protein Levels Dramatically Increase in Acute Pancreatitis

By LabMedica International staff writers
Posted on 25 Sep 2021
Print article
Histopathology of acute pancreatitis: necrosis of pancreatic parenchyma (lower left) with acute inflammation and fat necrosis (right and upper part of photograph) (Photo courtesy of Florida State University College of Medicine)
Histopathology of acute pancreatitis: necrosis of pancreatic parenchyma (lower left) with acute inflammation and fat necrosis (right and upper part of photograph) (Photo courtesy of Florida State University College of Medicine)
Heparin-binding protein (HBP), also known as CAP37 and azurocidin, is a glycoprotein stored in azurophilic granules and secretory vesicles in neutrophils that is released upon neutrophil activation early in the systemic inflammatory response.

Most patients with acute pancreatitis (AP) present with mild, self-limiting disease, with little or no need for hospital care. However, 20%–25% of patients develop a more severe and potentially life-threatening condition with progressive systemic inflammatory response syndrome (SIRS).

Clinical Scientists at the Skåne University Hospital (Malmö, Sweden) enrolled 260 patients with acute pancreatitis who were admitted to the hospital between 2010 and 2013. The mean age was 63.8 ± 18.7 years, and 50% of patients were female. EDTA plasma samples were obtained upon admission to the hospital, centrifuged at 2,000 rpm for 10 minutes (25 °C) and stored at − 80 °C until analysis.

Measured levels of heparin-binding protein upon hospital admission in 204 patients with confirmed acute pancreatitis served as the primary outcome. Secondary endpoints included associations between heparin-binding protein concentrations, disease severity and fluid balance. HBP concentration was determined by an enzyme-linked immunosorbent assay (ELISA), and in addition, C-reactive protein (CRP) was analyzed using standard methods.

The investigators reported that the overall median HBP concentration in this study was 529 (307–898) ng/mL. In mild pancreatitis, the median HBP level was 527 (301–887) ng/mL; in moderately severe cases, it was 529 (338–955) ng/mL; and in the severe group, the median HBP was 640 (383–1465) ng/mL. The CRP on the day of admission was 28 (11–59) mg/L, 30 (19–97) mg/L and 122 (83–170) mg/L in the mild, moderately severe and severe groups, respectively. The team also found that the fluid balance between patients with mild compared with moderately severe and severe pancreatitis was significantly different after day 2 (83 versus 510 versus 2,260 mL). However, there was no association between heparin-binding protein concentration and fluid balance.

The authors concluded that HBP levels are dramatically increased in patients with AP, and these levels far exceed those previously reported in other conditions. In their study, they did not observe any significant correlation between HBP levels and disease severity or the need for intravenous fluid. Additional studies on HBP are needed to further explore the role of HBP in the pathogenesis of AP and its possible clinical implications. The study was published on August 28, 2021 in the journal BMC Gastroenterology.

Related Links:

Skåne University Hospital

New
Gold Supplier
Molecular Diagnostic System
Singuway 9600 Pro
New
Gold Supplier
Fully Automated Batch Immunoanalyzer
Evidence+
New
COVID-19 Severity Algorithm
Atellica COVID-19 Severity Algorithm
New
Modular Syndromic Testing System
QIAstat-Dx (DiagCORE) Analyzer

Print article

Channels

Hematology

view channel
Image: Psoriatic plaques, showing a silvery center surrounded by a reddened border (Photo courtesy of Jane Bianchi, BA)

Hematological Parameters Compared in Psoriasis Patients

Psoriasis is a chronic, immune-mediated disorder that can involve the skin and/or joints. Four clinical types of psoriasis are currently recognized: psoriasis vulgaris (PsV), pustular psoriasis (PP), erythrodermic... Read more

Microbiology

view channel
Illustration

Sysmex Inostics Launches New Ultra-Sensitive Leukemia Blood Test for Early Detection of Cancer Cells Following Initial Therapy

Sysmex Inostics (Baltimore, MD, USA) has developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML) to better help in the fight... Read more

Technology

view channel
Image: QIAreach QuantiFERON-TB (Photo courtesy of QIAGEN N.V.)

Qiagen Launches Novel Tuberculosis Blood Test That Marks Quantum Leap from Traditional TB Skin Test

QIAGEN N.V. (Venlo, Netherlands) has announced the launch and CE marking of QIAreach QuantiFERON-TB test for tuberculosis (TB) infection, in order to help achieve global TB elimination targets by increasing... Read more

Industry

view channel
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)

Biohit’s Innovative GastroPanel Quick Test Receives CE Mark

Biohit Healthcare’s (Helsinki, Finland) GastroPanel Quick Test, the latest innovation in its unique GastroPanel product family, is now CE marked. The GastroPanel Quick Test is intended for diagnosing... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.